singl
bacteri
pathogen
isol
approxim
infect
uti
caus
coinfect
speci
approxim
caus
speci
bacteria
commonli
caus
uti
similar
dog
cat
fig
escherichia
coli
common
follow
gramposit
cocci
variou
other
includ
proteu
klebsiella
pasteurella
pseudomona
corynebacterium
sever
rare
report
genera
mycoplasma
spp
isol
urin
dog
clinic
sign
lower
urinari
tract
less
sampl
whether
mycoplasma
spp
associ
urinari
tract
diseas
cat
controversi
cat
may
infect
uniqu
strain
staphylococcu
staphylococcu
feli
commerci
phenotyp
identif
system
may
differenti
feli
coagulaseneg
staphylococcu
spp
one
studi
found
feli
third
common
isol
base
rdna
sequenc
n
bacteri
isol
cultur
suggest
feli
common
staphylococc
speci
caus
uti
cat
pyelonephr
infect
renal
pelvi
parenchyma
commonli
due
ascend
infect
lower
urinari
tract
dog
cat
fig
addit
compon
immun
protect
urinari
tract
gener
kidney
protect
bacteri
infect
vesicoureter
flap
valv
rel
long
uret
usual
allow
oneway
flow
urin
via
peristalsi
gener
hypox
environ
renal
medulla
inher
prostat
defens
mechan
infect
includ
local
immun
factor
immunoglobulin
antibacteri
protein
retrograd
flow
prostat
fluid
urin
urethr
peristalsi
urethr
high
pressur
zone
dog
bacteri
prostat
often
alter
normal
defens
underli
benign
prostat
hyperplasia
prostat
cyst
neoplasia
commonli
prostat
develop
ascend
bacteri
infect
may
result
prostat
abscess
addit
prostat
parenchym
infect
fig
hematogen
spread
prostat
secondari
cystiti
also
possibl
bacteri
pathogen
similar
caus
bacteri
cystiti
e
coli
common
see
fig
brucella
cani
also
consid
especi
intact
male
dog
caus
acut
chronic
prostat
normal
host
defens
mechan
effect
prevent
bacteri
uti
howev
impenetr
normal
host
defens
may
overwhelm
larg
quantiti
virul
uropathogen
introduc
urinari
tract
diagnost
therapeut
procedur
catheterassoci
bacteri
uti
common
complic
indwel
urinari
cathet
especi
openend
system
use
clinic
studi
infect
develop
dog
cat
indwel
urinari
cathet
risk
infect
increas
durat
catheter
risk
infect
compound
patient
preexist
urinari
tract
diseas
use
indwel
urinari
cathet
diuresi
corticosteroid
administr
particularli
danger
fungal
uti
uncommon
bacteri
uti
fungal
uti
occur
temporari
perman
breach
local
system
immun
lower
urinari
tract
funguria
may
due
primari
infect
lower
urinari
tract
secondari
shed
fungal
element
urin
anim
system
infect
primari
fungal
uti
commonli
due
candida
spp
commens
inhabit
genit
mucosa
upper
respiratori
tract
gastrointestin
tract
candida
albican
commonli
identifi
speci
follow
candida
glabrata
candida
tropicali
ubiquit
fungi
may
also
occasion
caus
primari
fungal
uti
includ
aspergillu
spp
blastomycosi
spp
fig
cryptococcu
spp
viralinduc
diseas
human
increasingli
recogn
especi
upper
urinari
tract
howev
difficult
determin
causeandeffect
relationship
viralinduc
diseas
may
occur
absenc
detect
replic
viru
sever
virus
implic
canin
felin
diseas
box
lower
urinari
tract
infect
bacteri
fungal
viral
lower
uti
may
symptomat
asymptomat
clinic
sign
indistinguish
caus
lower
urinari
tract
diseas
nonspecif
clinic
sign
lower
urinari
tract
diseas
includ
limit
pollakiuria
dysuria
stranguria
hematuria
inappropri
urin
prostat
acut
prostat
usual
associ
system
ill
includ
fever
anorexia
vomit
lethargi
dog
acut
diseas
may
also
caudal
abdomin
pain
stiff
gait
preputi
discharg
unwil
breed
contrast
dog
chronic
prostat
usual
system
ill
febril
commonli
recurr
uti
preputi
bloodi
discharg
clinic
sign
chronic
prostat
present
includ
stiff
gait
discomfort
rise
infertil
orchiepididym
dog
may
asymptomat
pyelonephr
pyelonephr
may
acut
chronic
present
acut
pyelonephr
usual
associ
sign
sever
system
ill
eg
uremia
fever
pain
kidney
possibl
nephromegali
andor
sepsi
contrast
chronic
pyelonephr
usual
insidi
present
slowli
progress
azotemia
may
associ
uremia
progress
kidney
damag
ultim
renal
failur
untreat
bacteri
pyelonephr
may
associ
hematuria
addit
clinic
sign
result
complet
urinalysi
may
provid
evid
bacteri
uti
hematuria
pyuria
bacteriuria
often
present
unless
suppress
immun
respons
underli
diseas
drug
fig
microscop
examin
unstain
urin
sediment
less
sensit
specif
examin
urin
sediment
stain
modifi
wright
stain
posit
urin
cultur
gold
standard
diagnos
bacteri
uti
quantit
urin
cultur
includ
isol
identif
organ
determin
number
bacteria
colonyform
unit
per
unit
volum
quantit
bacteria
enabl
interpret
signific
bacteria
present
urin
sampl
caution
exercis
interpret
quantit
urin
cultur
obtain
midstream
void
manual
express
urin
determin
whether
infect
uncompl
complic
essenti
guid
diagnost
therapeut
plan
simpl
uncompl
uti
occur
sporad
otherwis
healthi
anim
normal
structur
function
urinari
tract
contrast
infect
complic
involv
upper
urinari
tract
andor
prostat
underli
comorbid
alter
structur
function
urinari
tract
endocrinopathi
chronic
kidney
diseas
ckd
recurr
infect
recurr
infect
categor
relaps
refractorypersist
reinfect
superinfect
tabl
cat
bacteri
uti
complic
infect
addit
laboratori
test
imag
studi
often
requir
complic
infect
box
pyelonephr
pyelonephr
exampl
complic
uti
diagnosi
pyelonephr
usual
presumpt
base
posit
urin
cultur
concurr
consist
renal
diagnost
imag
abnorm
eg
pyelectasia
possibl
improv
degre
azotemia
follow
antimicrobi
therapi
although
posit
cultur
help
diagnosi
neg
urin
cultur
rule
pyelonephr
prostat
dog
suspect
prostat
diseas
complet
physic
examin
includ
rectal
examin
minimum
databas
complet
blood
count
chemistri
panel
urin
analysi
urin
cultur
abdomin
radiograph
ultrasound
use
determin
size
shape
locat
architectur
prostat
well
cyst
abscess
present
see
fig
prostat
fluid
evalu
cytolog
bacteri
cultur
sensit
see
fig
option
prostat
fluid
sampl
discuss
elsewher
includ
semen
evalu
third
fraction
prostat
wash
fineneedl
aspir
prostat
biopsi
catheterassoci
urinari
tract
infect
evid
support
routin
urin
cultur
cultur
urinari
cathet
tip
follow
remov
asymptomat
patient
cultur
predict
develop
catheterassoci
infect
contrast
urin
cultur
alway
indic
patient
clinic
sign
uti
fever
undetermin
origin
abnorm
urin
cytolog
ie
hematuria
pyuria
patient
develop
new
clinic
sign
fever
urinari
cathet
place
ideal
urin
cathet
remov
cystocentesi
perform
provid
sampl
cultur
bladder
fill
altern
origin
urinari
cathet
replac
urin
sampl
collect
second
cathet
less
ideal
sampl
urin
origin
cathet
sampl
collect
bag
never
use
asymptomat
bacteriuria
asymptomat
bacteriuria
ab
common
often
benign
find
healthi
women
risk
factor
includ
pregnanc
diabet
mellitu
spinal
cord
injuri
indwel
urinari
cathet
elderli
nurs
home
resid
women
ab
frequent
symptomat
episod
antimicrobi
treatment
decreas
number
episod
benefit
treatment
found
clinic
trial
human
wherea
potenti
complic
includ
advers
drug
reaction
develop
antimicrobi
resist
preval
ab
healthi
dog
cat
low
anim
underli
comorbid
hyperthyroid
diabet
mellitu
ckd
recurr
infect
increas
preval
ab
respect
prospect
studi
compar
clinic
outcom
veterinari
patient
without
antimicrobi
treatment
ab
one
recent
prospect
studi
dog
ab
transient
colon
persist
bacteriuria
time
period
dog
develop
clinic
sign
time
point
similar
gener
recommend
human
treatment
recommend
ab
unless
high
risk
ascend
system
infect
eg
immunocompromis
patient
ckd
diagnosi
fungal
uti
commonli
occur
identif
fungal
element
routin
concentr
urin
sediment
examin
fungal
cultur
sensit
ideal
treatment
especi
case
c
albican
tend
resist
routin
diagnost
test
includ
urin
analysi
light
microscopi
identifi
virus
viralinduc
diseas
viru
isol
gold
standard
diagnosi
techniqu
expens
timeconsum
requir
live
replic
viru
diagnost
polymeras
chain
reaction
assay
rapid
sensit
method
optim
nucleic
acid
prepar
essenti
nucleic
acid
easili
degrad
urin
antimicrobi
drug
cornerston
treatment
uti
case
antimicrobi
agent
chosen
base
suscept
test
uropathogen
overus
misus
antimicrobi
drug
may
result
emerg
resist
organ
situat
implic
success
treatment
infect
patient
well
overal
veterinari
human
health
patient
uncompl
uti
clinic
sign
sever
enough
merit
therapi
result
urin
cultur
sensit
test
receiv
broadspectrum
antimicrobi
excel
urin
penetr
suggest
firstlin
antimicrobi
uncompl
uti
includ
amoxicillin
cephalexin
trimethoprimsulfamethoxazol
tabl
use
potenti
blactam
ie
amoxicillinclavulan
acid
fluoroquinolon
extendedreleas
cephalexin
ie
cefovecin
inappropri
uncompl
uti
reserv
complic
resist
infect
tabl
multipl
bacteria
isol
rel
import
must
assess
base
quantif
suspect
pathogen
ideal
antimicrobi
effect
pathogen
select
possibl
combin
therapi
multipl
antimicrobi
may
consid
assum
evid
pyelonephr
increas
risk
ascend
infect
target
antimicrobi
therapi
pathogen
clinic
relev
reason
exampl
anecdot
resolut
enterococcu
sp
infect
often
possibl
treatment
concurr
infect
use
fluoroquinolon
empir
treatment
bacteri
uti
discourag
inher
resist
mani
gramposit
organ
class
antimicrobi
develop
resist
mani
gramneg
organ
includ
e
coli
class
drug
studi
found
variabl
crossresist
among
differ
gener
fluoroquinolon
except
pradofloxacin
veraflox
fluoroquinolon
resist
develop
later
gener
drug
may
benefici
vitro
pradofloxacin
thirdgener
fluoroquinolon
outperform
fluoroquinolon
term
potenc
efficaci
enrofloxacin
least
potent
second
ciprofloxacin
molecular
alter
pradofloxacin
allow
increas
bactericid
activ
decreas
propens
antimicrobi
resist
featur
make
pradofloxacin
attract
choic
suscept
isol
pathogen
reduc
fluoroquinolon
suscept
current
pradofloxacin
licens
felin
skin
infect
unit
state
wherea
european
licens
includ
wide
rang
indic
dog
cat
one
prospect
clinic
trial
n
found
pradofloxacin
effect
welltoler
felin
bacteri
uti
experiment
studi
cat
treat
time
recommend
dose
experi
retin
toxic
human
medicin
shortdur
antimicrobi
therapi
commonli
trimethoprimsulfamethoxazol
fluoroquinolon
becom
standard
treatment
acut
uncompl
bacteri
cystiti
women
recommend
antimicrobialspecif
antimicrobi
compar
efficaci
given
treatment
benefit
shorter
therapi
includ
better
complianc
lower
cost
decreas
advers
effect
goal
treatment
decreas
bacteri
load
enough
control
clinic
sign
immun
system
elimin
remain
organ
two
recent
prospect
random
studi
evalu
shortdur
treatment
dog
uncompl
bacteri
uti
first
studi
compar
highdos
enrofloxacin
n
mgkg
oral
everi
hour
standard
dose
amoxicillinclavulan
acid
n
mgkg
oral
everi
hour
clinic
microbiolog
cure
evalu
day
antimicrobi
discontinu
shortterm
highdos
treatment
inferior
standard
treatment
second
studi
doubleblind
compar
trimethoprimsulfamethoxazol
n
mgkg
oral
everi
hour
plu
placebo
day
cephalexin
n
mgkg
oral
everi
hour
signific
differ
shortterm
treatment
longterm
treatment
clinic
microbiolog
cure
rate
treatment
group
clinic
cure
day
microbiolog
cure
addit
studi
need
determin
appropri
treatment
durat
uncompl
bacteri
uti
antimicrobi
therapi
initi
wait
cultur
sensit
result
empir
antimicrobi
efficaci
gramneg
bacteria
common
pathogen
fluoroquinolon
good
first
choic
see
tabl
acut
pyelonephr
requir
hospit
parenter
antimicrobi
therapi
intraven
fluid
parenter
therapi
continu
patient
eat
drink
normal
azotemia
longer
improv
intens
therapi
infect
treat
complic
uti
minimum
week
antibiot
regular
monitor
recurr
infect
follow
therapi
chronic
pyelonephr
treat
complic
uti
well
patient
usual
requir
hospit
initi
diagnosi
bloodprost
barrier
compromis
acut
prostat
appropri
antimicrobi
select
base
cultur
sensit
treat
complic
uti
minimum
week
antimicrobi
must
select
care
case
chronic
prostat
bloodprost
barrier
gener
intact
see
tabl
nonion
basic
lipidsolubl
antimicrobi
best
penetr
prostat
tissu
drug
trimethoprimsulfamethoxazol
chloramphenicol
enrofloxacin
ciprofloxacin
excel
choic
exampl
drug
lowlipid
solubl
poor
diffus
across
bloodprost
barrier
includ
penicillin
cephalothin
antimicrobi
given
minimum
week
cultur
prostat
fluid
perform
discontinu
antimicrobi
castrat
recommend
adjunct
treatment
medic
manag
help
reduc
prostat
size
speed
recoveri
decreas
recurr
finasterid
inhibitor
may
consid
valuabl
breed
anim
owner
refus
surgeri
although
seem
logic
administ
antimicrobi
agent
indwel
urinari
cathet
insert
effort
decreas
iatrogen
infect
practic
strongli
discourag
concomit
oral
parenter
administr
antimicrobi
agent
indwel
urethr
catheter
prevent
develop
bacteri
uti
promot
infect
caus
multidrugresist
bacteria
fluconazol
recommend
initi
treatment
patient
high
margin
safeti
sensit
strain
candida
spp
excret
activ
drug
urin
high
concentr
tabl
candida
spp
c
albican
like
resist
fluconazol
antifung
sensit
test
recommend
determin
higher
dose
fluconazol
appropri
anoth
drug
use
although
amphotericin
b
renal
excret
achiev
high
concentr
urin
often
use
parenter
administ
nephrotox
commonli
use
antifung
drug
includ
itraconazol
ketoconazol
renal
excret
activ
form
secondari
fungal
uti
occur
shed
organ
urin
patient
system
infect
organ
commonli
associ
urin
shed
aspergillu
spp
dog
particularli
german
shepherd
dog
cryptococcu
spp
cat
patient
treat
antifung
agent
standardli
recommend
system
infect
antivir
drug
evalu
anim
viralinduc
urinari
tract
diseas
manag
patient
limit
support
care
bacteri
interfer
refer
use
lowvirul
nonpathogen
bacteria
compet
decreas
risk
colon
infect
pathogen
organ
commonli
use
bacteria
includ
e
coli
strain
lactobacillu
sp
propos
mechan
action
includ
competit
nutrient
attach
site
bacteriocidin
antibioticprotein
product
biofilm
prevent
host
immunomodul
treatment
strategi
infanc
even
human
medicin
preliminari
studi
promis
especi
patient
spinal
cord
injuri
neurogen
bladder
experiment
protocol
colon
canin
urinari
tract
e
coli
describ
anoth
potenti
futur
applic
prevent
catheterassoci
uti
alter
vagin
microflora
particular
lactic
acidproduc
bacteria
lab
may
play
role
establish
uti
exampl
women
recurr
uti
often
deplet
vagin
lactobacillu
sp
wherea
increas
vagin
colon
lactobacillu
sp
associ
reduc
number
recurr
uti
human
lactobacillu
sp
common
lab
wherea
enterococcu
canintestini
common
speci
dog
lab
creat
acid
environ
inhibit
uropathogen
colon
modul
host
immun
function
may
downregul
virul
factor
express
pathogen
bacteria
probiot
form
bacteri
interfer
recommend
treatment
prophylaxi
strategi
women
probiot
restor
lactobacillu
sp
vagin
flora
displac
potenti
uropathogen
vagina
two
studi
dog
evalu
vagin
microflora
probiot
administr
found
signific
differ
howev
prospect
studi
need
evalu
role
probiot
lower
urinari
tract
diseas
veterinari
speci
probiot
market
vari
bacteri
speci
potenc
number
colonyform
unit
viabil
addit
gastrointestin
microb
immunomodulatori
effect
throughout
bodi
impact
gastrointestin
probiot
local
urinari
tract
immun
function
evalu
consensu
regard
appropri
durat
treatment
tabl
uncompl
uti
usual
success
treat
standard
cours
appropri
antimicrobi
agent
evid
shorter
treatment
ie
day
inferior
standard
durat
therapi
research
need
area
proper
antimicrobi
chosen
administ
appropri
dosag
frequenc
clinic
sign
result
complet
urin
analysi
resolv
within
hour
possibl
urin
cultur
perform
day
cessat
antimicrobi
therapi
uncompl
infect
rare
cat
inher
resist
bacteri
uti
typic
predispos
caus
optim
durat
therapi
unknown
antimicrobi
usual
administ
minimum
week
urin
evalu
cultur
first
week
treatment
respons
therapi
discontinu
therapi
day
month
therapi
discontinu
necessari
treat
bacteriuria
associ
indwel
cathet
clinic
cytolog
evid
infect
fig
patient
develop
catheterassoci
uti
treatment
like
success
cathet
remov
infect
may
treat
uncompl
histori
recurr
infect
relev
comorbid
otherwis
infect
urinari
tract
infect
treat
complic
week
appropri
antimicrobi
base
cultur
sensit
primari
fungal
uti
alway
treat
complic
infect
minimum
week
antifung
therapi
regular
monitor
cessat
therapi
sever
strategi
decreas
risk
catheterassoci
uti
box
prophylact
antimicrobi
therapi
recurr
infect
good
studi
evalu
puls
intermitt
chronic
lowdos
prophylact
antimicrobi
therapi
anim
frequent
reinfect
anecdot
anim
may
benefit
box
care
patient
select
requir
impact
promot
antimicrobi
resist
consid
prophylact
treatment
undertaken
urin
cultur
suscept
test
done
ensur
bacteri
uti
erad
longterm
prophylaxi
drug
excret
high
concentr
urin
unlik
caus
advers
effect
select
often
fluoroquinolon
cephalosporin
blactam
antimicrobi
chosen
antimicrobi
agent
administ
approxim
onethird
therapeut
daili
dose
immedi
patient
void
time
drug
metabolit
retain
urinari
tract
hour
typic
night
drug
given
minimum
month
urin
sampl
prefer
collect
cystocentesi
catheter
may
induc
bacteri
uti
collect
everi
week
urinalysi
quantit
urin
cultur
sampl
free
infect
prophylact
treatment
continu
bacteri
uti
identifi
activ
breakthrough
infect
treat
complic
bacteri
uti
return
prophylact
strategi
breakthrough
bacteri
uti
occur
month
prophylact
antimicrobi
therapi
treatment
may
discontinu
patient
monitor
reinfect
dmannos
dmannos
use
prevent
recurr
uti
studi
clinic
efficaci
veterinari
patient
dmannos
sugar
competit
bind
mannosefimbria
certain
e
coli
strain
therebi
inhibit
adhes
uroepithelium
littl
data
avail
bacteria
may
express
mannos
fimbria
extrapol
anecdot
dose
dog
onequart
teaspoon
per
pound
time
daili
methenamin
methenamin
salt
urinari
antisept
convert
bacteriostat
formaldehyd
acid
environ
urin
ph
controversi
human
medicin
whether
methenamin
prevent
uti
although
evid
may
effect
shortterm
prophylaxi
unknown
salt
describ
literatur
hippur
mandel
equal
effect
mandel
salt
difficult
find
limit
veterinari
literatur
use
methenamin
small
anim
although
theoret
benefit
studi
safeti
efficaci
appropri
dose
lack
commonli
recommend
dose
mgkg
oral
everi
hour
dog
mg
per
cat
oral
everi
hour
gastrointestin
upset
dysuria
commonli
report
advers
event
methenamin
poorli
toler
felin
patient
methenamin
use
case
renal
failur
concurr
use
urinari
acidifi
dlmethionin
usual
requir
maxim
effect
cranberri
proanthocyanidin
activ
ingredi
cranberri
alter
genotyp
phenotyp
express
fimbria
subsequ
inhibit
e
coli
adher
human
bladder
vagin
epitheli
cell
studi
human
reveal
inconsist
efficaci
prevent
uti
howev
metaanalysi
n
human
supplement
cranberri
product
less
uti
period
compar
placebo
veterinari
studi
healthi
dog
felin
studi
addit
qualiti
potenc
variabl
among
overthecount
product
ideal
urinari
tract
infect
formul
would
test
speci
interest
consensu
antimicrobi
guidelin
work
group
intern
societi
companion
anim
infecti
diseas
insuffici
evid
support
use
cranberri
extract
prevent
recurr
uti
dog
cat
local
therapi
local
infus
antimicrobi
antisept
dimethyl
sulfoxid
irrit
retain
within
urinari
bladder
anecdot
instil
dilut
chlorhexidin
andor
ethylenediaminetetraacet
acid
edta
tromethamin
edtatri
via
cystotomi
tube
may
decreas
incid
bacteri
uti
bartg
jw
person
commun
knoxvil
tn
small
human
studi
bladder
irrig
dilut
chlorhexidin
significantli
decreas
postop
bacteriuria
although
elimin
preexist
infect
appear
damag
bladder
mucosa
postul
edtatri
synergist
effect
system
antimicrobi
well
local
chlorhexidin
irrig
propos
mechan
includ
dival
ion
bind
caus
alter
bacteri
dna
synthesi
cell
wall
permeabl
ribosom
stabil
addit
vitro
studi
suggest
presenc
edtatri
reduc
minimum
inhibitori
concentr
variou
antimicrobi
drug
small
studi
n
dog
n
chronic
cystiti
daili
local
infus
via
steril
urinari
cathet
ml
edta
c
day
well
toler
dog
neg
urin
cultur
day
treatment
addit
studi
need
determin
shortand
longterm
effect
edtatri
therapi
emerg
multidrugresist
bacteria
concern
import
implic
patient
public
health
trend
toward
increas
resist
fecal
environment
reservoir
addit
acquir
resist
gene
via
plasmid
bacteri
strategi
persist
within
urinari
tract
exampl
uropathogen
e
coli
invad
persist
within
superfici
bladder
wall
epitheli
cell
bacteria
may
remain
dormant
period
time
follow
recrudesc
biofilm
bacteria
capac
biofilm
format
facilit
colon
biofilm
compos
organ
adher
togeth
selfproduc
polysaccharid
matrix
suggest
bacteria
within
biofilm
becom
sessil
protect
immun
system
antimicrobi
inher
resist
shear
forc
remov
human
bacteria
capac
produc
biofilm
associ
ab
biofilm
also
implement
develop
catheterassoci
uti
strategi
prevent
catheterassoci
biofilm
includ
use
materi
less
amend
biofilm
format
coat
surfac
modif
decreas
biofilm
format
exampl
silicon
cathet
prefer
latex
scan
electron
microscop
imag
reveal
latex
surfac
irregular
promot
microbi
adher
exampl
agent
use
cathet
coat
antisept
chlorihexidin
veterinari
prospect
studi
n
dog
evalu
biofilm
format
indwel
urinari
cathet
sustainedreleas
varnish
chlorihexidineco
urinari
cathet
statist
decreas
biofilm
format
array
cathet
coat
modif
decreas
bacteri
adher
biofilm
format
primarili
studi
research
set
includ
silver
coat
nanoparticl
iontophoresi
antimicrobi
ureas
enzym
inhibitor
liposom
bacteriophag
novel
strategi
includ
quorum
sens
inhibitor
vibroacoust
stimul
box
detail
discuss
comparison
beyond
scope
articl
reader
refer
elsewher
oral
antimicrobi
particular
combin
therapi
clarithromycin
shown
promis
vitro
antibiofilm
activ
exampl
pseudomona
aeruginosa
biofilm
elimin
synergist
combin
clarithromycin
ciprofloxacin
likewis
combin
therapi
clarithromycin
fosfomycin
effect
either
treatment
alon
reduc
staphylococcu
pseudintermediu
biofilm
vivo
studi
need
evalu
efficaci
therapi
infect
fail
respond
complet
fluconazol
recultur
antifung
sensit
test
perform
see
tabl
suscept
isol
may
respond
intravesicular
administr
clotrimazol
amphotericin
b
urinari
alkalin
also
histor
propos
adjunct
therapi
patient
fungal
uti
increas
urin
ph
may
inhibit
fungal
growth
howev
current
favor
treatment
fungal
uti
human
question
efficaci
veterinari
patient
complic
magnesium
ammonium
phosphat
struvit
urolithiasi
staphylococcu
spp
proteu
spp
rare
corynebacterium
spp
klebsiella
spp
ureaplasma
spp
may
produc
ureas
box
enzym
hydrolyz
urea
ammonia
buffer
urin
hydrogen
ion
form
ammonium
ion
increas
urin
ph
increas
dissolv
ionic
phosphat
presenc
magnesium
magnesium
ammonium
phosphat
struvit
may
precipit
around
nidu
form
urolith
fig
bacteria
incorpor
urolith
matrix
thu
consid
complic
uti
poor
antimicrobi
penetr
greater
struvit
urolith
dog
induc
ureaseproduc
bacteria
wherea
struvit
urolith
cat
commonli
steril
ie
associ
bacteri
uti
struvit
urolith
dissolv
combin
dietari
therapi
appropri
antimicrobi
therapi
follow
dissolut
remov
prevent
urolith
recurr
requir
prevent
reinfect
dog
uncomfort
symptomat
urocystolithiasi
andor
fail
medic
manag
minim
invas
procedur
laser
lithotripsi
laparoscopicassist
cystotomi
cystotomi
may
consid
chronic
bacteri
infect
may
induc
microscop
macroscop
bladder
mucos
prolifer
intramur
accumul
inflammatori
cell
polypoid
cystiti
occur
epitheli
prolifer
sever
result
masslik
lesion
diffus
thicken
bladder
wall
fig
gross
differenti
polypoid
cystiti
bladder
wall
neoplasm
reliabl
howev
polypoid
cystiti
like
develop
bladder
apex
vs
transit
cell
carcinoma
commonli
found
bladder
trigon
commonli
botryoid
appear
rather
fimbriat
grossli
vascular
transit
cell
carcinoma
proteu
spp
may
commonli
associ
develop
lesion
polypoid
cystiti
lesion
nidus
deepseat
bacteri
infect
treat
complic
uti
case
longterm
antimicrobi
therapi
may
result
success
resolut
lesion
howev
partial
cystectomi
result
rapid
resolut
clinic
sign
like
associ
improv
rate
longterm
resolut
infect
allow
shorter
antimicrobi
treatment
cours
emphysemat
cystiti
refer
accumul
air
within
bladder
wall
lumen
secondari
infect
glucosefer
bacteria
case
due
e
coli
infect
proteu
spp
clostridum
spp
aerobact
aerogen
also
report
emphysemat
cystiti
commonli
develop
dog
cat
diabet
mellitu
high
concentr
ferment
substrat
treatment
emphysemat
cystiti
describ
complic
uti
glucosuria
present
appropri
treatment
initi
underli
caus
although
systemat
review
pyelonephr
dog
cat
perform
anim
system
compromis
immun
ie
hyperadrenocortic
diabet
mellitu
dog
cat
ckd
patient
caus
vesicoureter
reflux
like
predispos
develop
pyelonephr
chronic
pyelonephr
like
underdiagnos
caus
renal
failur
dog
cat
especi
consid
patient
previous
stabl
ckd
unexpect
worsen
azotemia
ie
acuteonchron
renal
failur
prostat
abscess
sequela
prostat
character
purul
fluid
accumul
within
prostat
tissu
clinic
sign
variabl
depend
size
extent
abscess
well
system
involv
prostat
abscess
gener
easili
identifi
ultrasonographi
goal
therapi
provid
drainag
either
ultrasoundguid
percutan
drainag
surgeri
surgic
option
includ
partial
prostatectomi
prostat
oment
determin
whether
infect
uncompl
complic
essenti
guid
diagnost
therapeut
plan
recurr
infect
complic
infect
may
relaps
refractori
persist
reinfect
superinfect
antimicrobi
cornerston
treatment
bacteri
uti
ideal
select
base
cultur
sensit
limit
literatur
support
prevent
therapi
identif
resolut
underli
caus
essenti
